Loading
Sino Biopharmaceutical Ltd. Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Cheng Cheung Ling, was filed 30 Apr 2026.
Insider Decl.
80
Thresholds
n/a
Buy Volume
€198M
68 ops. · all time
Sell Volume
€624M
9 ops. · all time
Who traded when
BuySaleCheng Cheung Ling3 buys
Tse Hsin3 buys
Tse Ping2 buys
Tse Theresa Y Y1 buy
Since the insiders bought
- -7.7%Entry HK$5.48 · Close at T+90 HK$5.06
- -3.5%Entry HK$5.42 · Close at T+90 HK$5.23
- -12.5%Entry HK$5.89 · Close at T+90 HK$5.15
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Sino Biopharmaceutical Ltd. Strong Buy (bullish), based on 23 analysts. Average price target: HK$8.46.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,394 of 26,289 companies
62.5
score / 100
Value55
Quality70
FCF yld8.1%
Earn yld2.5%
EV/EBITDA13.0x
ROE14%
Gross mgn82%
Net mgn7.4%
Debt/EBITDA1.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$5.25
Analyst consensus
23 analystsStrong buy
HK$5.94Target HK$8.46(+61%)HK$10.97
Income statement
RevenueHK$31.8B
Gross profitHK$26.1B82% margin
EBITDAHK$8.4B26% margin
Net incomeHK$2.3B7.1% margin
Valuation
PER (trailing)35.0x
PER (forward)19.5x
P/Book2.5x
Beta0.61
Balance sheet & cash
Market capHK$93.5B
Total debtHK$16.1B
Free Cash FlowHK$7.6B
Debt / Equity37%
Profitability & ownership
ROE14.1%
ROA7.5%
% insiders48.7%
% institutions23.2%
Last declaration on 30 April 2026
Declarations80 total
1,000,000 shares@ HK$5.4410.0059% mcap20.0% of flowShareXHKGHKEX:DA20260430E00374
Canonical exit: 29 Jul 2026 (T+90)
1,000,000 shares@ HK$5.47050.0060% mcap20.2% of flowShareXHKGHKEX:DA20260429E00338
Canonical exit: 28 Jul 2026 (T+90)
2,000,000 shares@ HK$5.52350.012% mcap34.8% of flowShareXHKGHKEX:DA20260429E00271
Canonical exit: 28 Jul 2026 (T+90)
3,000,000 shares@ HK$5.42820.018% mcap59.9% of flowShareXHKGHKEX:DA20260428E00209
Canonical exit: 27 Jul 2026 (T+90)
3,496,000 shares@ HK$5.87490.024% mcap65.2% of flowShareXHKGHKEX:DA20260331E00251
Canonical exit: 29 Jun 2026 (T+90)
1,748,000 shares@ HK$5.730.012% mcap100.0% of flowShareXHKGHKEX:DA20260330E00223
Canonical exit: 28 Jun 2026 (T+90)
1,000,000 shares@ HK$6.40682.1% of flowShareXHKGHKEX:DA20251224E00041
Canonical exit: 24 Mar 2026 (T+90)
1,000,000 shares@ HK$7.3682.5% of flowShareXHKGHKEX:DA20250820E00018
Canonical exit: 18 Nov 2025 (T+90)
1,000,000 shares@ HK$6.472.2% of flowShareXHKGHKEX:DA20250716E00152
Canonical exit: 14 Oct 2025 (T+90)
13,800,000 shares@ HK$3.72170.8% of flowShareXHKGHKEX:DA20241004E00082
2,000,000 shares@ HK$2.589120.4% of flowShareXHKGHKEX:DA20240423E00253
Canonical exit: 22 Jul 2024 (T+90)
14,301,117 sharesShareXHKGHKEX:DA20240419E00025
14,301,117 sharesShareXHKGHKEX:DA20240419E00027
Canonical exit: 16 Jul 2024 (T+90)
5,000,000 shares@ HK$2.3239100.0% of flowShareXHKGHKEX:DA20240419E00300
Canonical exit: 18 Jul 2024 (T+90)
2,500,000 shares@ HK$2.322323.0% of flowShareXHKGHKEX:DA20240419E00068
Canonical exit: 18 Jul 2024 (T+90)
2,081,643,374 sharesShareXHKGHKEX:DA20240411E00035
Canonical exit: 7 Jul 2024 (T+90)
197,611,387 sharesShareXHKGHKEX:DA20240411E00037
Canonical exit: 7 Jul 2024 (T+90)
2,279,254,761 sharesShareXHKGHKEX:DA20240411E00034
5,000,000 shares@ HK$3.44240.3% of flowShareXHKGHKEX:DA20230706E00370
Canonical exit: 4 Oct 2023 (T+90)
7,000,000 shares@ HK$3.50160.4% of flowShareXHKGHKEX:DA20230705E00337
Canonical exit: 3 Oct 2023 (T+90)
10,000,000 shares@ HK$3.55450.6% of flowShareXHKGHKEX:DA20230704E00280
Canonical exit: 2 Oct 2023 (T+90)
5,000,000 shares@ HK$3.45040.3% of flowShareXHKGHKEX:DA20230703E00260
Canonical exit: 1 Oct 2023 (T+90)
10,000,000 shares@ HK$3.39740.5% of flowShareXHKGHKEX:DA20230630E00279
Canonical exit: 28 Sept 2023 (T+90)
1,500,000 shares@ HK$3.4019.8% of flowShareXHKGHKEX:DA20230630E00378
Canonical exit: 28 Sept 2023 (T+90)
2,000,000 shares@ HK$4.11472.5% of flowShareXHKGHKEX:DA20230404E00370
Canonical exit: 3 Jul 2023 (T+90)
25 of 80 declarations
About Sino Biopharmaceutical Ltd.
Sino Biopharmaceutical, a healthcare group listed in Hong Kong (HKD 93.5 billion, 48.7% of the capital held by insiders), is carried by directors: Tse Ping (24 filings, 20 purchases), Tse Hsin (23, including 22 purchases), Cheng Cheung Ling (16) and Tse Theresa Y Y (8). Of 80 filings published between March 5, 2018 and April 30, 2026, 68 are purchases against 9 sales, or 88% purchases.
The 54 purchases with an amount weigh EUR 198.0 million, median EUR 1,380,470. The largest, EUR 51.2 million, dates from December 7, 2020 (Tse Ping), ahead of EUR 18.1 million by Cheng Cheung Ling on December 7, 2018. Sales are fewer but heavier: Tse Ping sold EUR 346.7 million on July 28, 2020 and EUR 271.7 million on April 23, 2020. Between April 8 and April 23, 2024, 5 insiders bought.
Read moreShow less
Yearly volume runs from 1 filing in 2022 to 21 in 2020. For 54 purchases a 90-day result is stored: a median of minus 12%, with 28% positive (recorded past results, not a forecast). The 7 filings of the last twelve months are all purchases. Publication is the same day in median terms (0 days).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
